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Abstract
FK506 binding protein 5 (FKBP5) belongs to a family of immunophilins named for their ability to bind immunosup-
pressive drugs, also known as peptidyl-prolyl cis-trans isomerases, and also with chaperones to help protein fold-
ing. Using glioma cDNA microarray analysis, we found that FKBP5 was overexpressed in glioma tumors. This
finding was further validated by real-time reverse transcription–polymerase chain reaction and Western blot anal-
ysis. The roles of FKBP5 in glioma cells were then examined. We found that cell growth was suppressed after
FKBP5 expression was inhibited by short interfering RNA transfection and enhanced by FKBP5 overexpression.
Electrophoretic mobility shift assay showed that nuclear factor–kappa B (NF-κB) and DNA binding was enhanced
by FKBP5 overexpression. The expression level of I-kappa B alpha and phosphorylated NF-κB was regulated by the
expression of FKBP5. These data suggest that FKBP5 is involved in NF-κB pathway activation in glioma cells. In
addition, FKBP5 overexpression in rapamycin-sensitive U87 cells blocked the cells’ response to rapamycin treat-
ment, whereas rapamycin-resistant glioma cells, both PTEN-positive and -negative, were synergistically sensitive
to rapamycin after FKBP5 was knocked down, suggesting that the FKBP5 regulates glioma cell response to rapa-
mycin treatment. In conclusion, our study demonstrates that FKBP5 plays an important role in glioma growth and
chemoresistance through regulating signal transduction of the NF-κB pathway.
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Introduction
FK506 binding proteins (FKBPs) belong to a family of immunophi-
lins that were named for their ability to bind immunosuppressive
drugs. FK506 binding proteins have peptidyl-prolyl isomerase
(PPIase) activity; that is, they produce cis-trans–isomerization of pro-
lyl bonds in different states of a target protein, which is important for
protein folding [1,2]. FK506 binding proteins can associate with
chaperones and constitute a major part of the receptor complexes [3].
The PPIase activity of FKBPs can be inhibited by FK506 and rapa-
mycin. The most well-known FKBP family member is FKBP12, a
small peptide with single FKBP domain and a molecular size of
12 kDa. FKBP12 is involved in multiple biologic processes. One
of the most well-known processes is binding to rapamycin and form-
ing a complex with mammalian target of rapamycin (mTOR) to me-
diate phosphatidylinositol 3-kinase/Akt/mTOR downstream signal
transduction, which is the major mechanism for applying rapamycin
in tumor treatment [3].
FK506 binding protein 5 (FKBP5) is a 51-kDa FK506 binding
protein with PPIase activity, also named as FKBP51. Human FKBP5
was first cloned from a HeLa cell cDNA library [4]. Different from
small FKBPs that are enriched in neurons throughout the central and
peripheral nervous systems [5], FKBP5 protein was not able to be
identified in brain tissue using Western blot analysis [6], and the
mRNA level of FKBP5 detected by Northern blot assay was relatively
low in human brain tissue [4].
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FKBP5 contains two FKBP domains at N-terminus and three tet-
ratricopeptide repeats (TPR) motifs. The C-terminal region of
FKBP5, along with the TPR motifs, contributes to heat shock pro-
tein HSP90/HSP70 binding [7,8]. The dynamic formation of het-
erocomplexes with HSP90 and FKBP5/FKBP52 is required for
modulating the translocation of steroid receptors, such as progester-
one and glucocorticoid receptors to nucleus [9,10]. FKBP5 was also
demonstrated to bind with calcineurin through C-terminal domain
including TPR motifs of FKBP5. This interaction is independent of
calcium, calmodulin, and drug [11]. Studying the map of tumor ne-
crosis factor-alpha/nuclear factor–kappa B (NF-κB) signal transduc-
tion, FKBP5 was found to associate with mitogen-activated protein
kinase kinase kinase 1 (MAP3K1), mitogen-activated protein kinase
kinase kinase 7 (MAP3K7), inhibitor of nuclear factor κ-B kinase α
subunit (IKKα), inhibitor of nuclear factor κ-B kinase ɛ subunit
(IKKɛ), and C-rel proto-oncogene protein (cRel) [12]. FKBP5 exerts
peptidyl-prolyl isomerase activity that catalyzes the isomerization of
peptidyl-prolyl imide bonds in an α subunit of the IKK kinase com-
plex and is required for IKK function [12]. FKBP5 was also found to
be essential for drug-induced NF-κB activation in leukemia and vas-
cular smooth muscle cells [13,14]. These findings suggest that
FKBP5 plays a crucial biologic role in cells.
The majority of studies on the biologic function of FKBP5 were
focused on lymphocytes, although FKBP5 has been found in many
tissues [4,6]. FKBP5 mRNA was detected in glioma cell line U251
cells by reverse transcription–polymerase chain reaction (RT-PCR)
[15], and melanoma cells [16]; however, the expression, biologic
function, and molecular mechanisms of FKBP5 in tumor cells, espe-
cially brain tumors, are not well known. In this paper, we report the
association of FKBP5 expression levels with glioma grade, as well as
explore possible functions of FKBP5 in glioma. We used RNA inter-
ference technique to knock down the expression of FKBP5 in glioma
cells and demonstrated that FKBP5 expression mediated survival of
glioma cells as well as glioma cell response to rapamycin treatment.
Materials and Methods
Materials
Monoclonal anti-FKBP51 antibody was purchased from BD Bio-
sciences (San Jose, CA). Polyclonal anti–I-kappa B alpha (IκBα)
antibody was purchased from Cell Signaling Technology (Beverly,
MA). silMPORTER siRNA/plasmid DNA transfection reagent was
purchased from Upstate Inc. (Charlottesville, VA). LightShift Chemi-
luminescent Electrophoretic Mobility Shift Assay (EMSA) kit was
purchased from Pierce (Rockford, IL). A Nuclear Extraction Kit
was obtained from Chemicon International (Temecula, CA). FKBP5
cDNA was purchased from OriGene (Rockville, MD).
Glioma Cells
The glioma cell lines, A172, U87, U251, LN18, LNZ308,
LN443, and LN229, purchased from American Type Culture Col-
lection (Manassas, VA), were grown on tissue culture dishes in me-
dium consisting of DMEM containing 10% fetal calf serum, 2 mM
glutamine, 50 U/ml penicillin, and 0.05 mg/ml streptomycin.
Tumor Samples
Glioma tumor samples from 192 patients were obtained from the
Glioma Biorepository at Henry Ford Hospital, Detroit, MI. All tumor
samples were obtained with written consent in accordance with insti-
tutional guidelines. Tumor histologies included 81 glioblastomas mul-
tiforme (GBMs), 49 oligodendrogliomas, 28 astrocytomas, 11 mixed
gliomas, and 21 nontumor brain tissues obtained from epilepsy sur-
gery. All tissues had been flash frozen and stored at −80°C.
Microarray Construction
We used an array, constructed at the Neuro-Oncology Branch of
the National Cancer Institute (NCI)/National Institute of Neurolog-
ical Disorders and Stroke (NINDS), containing the 28,896 Research
Genetics cDNAs (15,935 of them have been sequence-verified) and
an additional 5664 Cancer Genome Anatomy Project sequence-
verified cDNAs obtained through data mining of the Cancer Genome
Anatomy Project databases. The clones we selected were those related
to genes that had previously been described as potentially important
for cancer or glioma development, such as genes involved in invasion,
angiogenesis, and transformation. We also selected a series of clones
that have been previously shown to be highly over- or underexpressed
in the glioma Serial Analysis and Gene Expression database. Finally,
we incorporated a number of cDNA clones that were obtained by
screening approximately 20 glioma cDNA libraries for highly repre-
sented and/or unusual transcripts. The arrays were printed using a mi-
croarrayer (OmniGrid; GeneMachines, San Carlos, CA) on poly-l-
lysine–coated glass slides.
RNA Preparation and Microarray Experiments
Total RNA was isolated using TRIzol (Life Technologies, Rock-
ville, MD) according to the manufacturer’s instructions. The RNA
was further purified using RNeasy Mini kit (Qiagen Inc., Valencia,
CA). Total RNA was then linearly amplified one round as previously
described [17]. Amplified RNA (1 μg) was reverse-transcribed and
labeled directly with Cy3-dUTP and Cy5-dUTP using a cDNA la-
beling kit according to the manufacturer’s instructions (Amersham
Inc., Piscataway, NJ). Tissue sample RNA was labeled with Cy5,
and Universal Human Reference RNA (Stratagene, La Jolla, CA)
was labeled with Cy3. Labeled cDNAs were hybridized to the
34,561-feature glass cDNA microarrays overnight at 42°C with
25% formamide. The arrays were scanned on a microarray scanner
(GenePix 4000A; Axon Instruments, Foster City, CA) to generate
TIFF images. A microarray analysis software (GenePix Pro 3.0; Axon
Instruments) was used to measure fluorescence signals. All of the
array data were deposited in the NCI/Center for Information Tech-
nology microarray database (http://nciarray.nci.nih.gov/).
Short Interfering RNA Transfection
siRNA duplexes were synthesized and purified by Dharmacon
(Lafayette, CO). We used a pool of four FKBP5 siRNA duplexes,
which were also obtained from Dharmacon. Transfection of siRNAs
was done using 100 nM FKBP5 or scrambled control siRNAs and
silMPORTER kit (Upstate Inc.) according to the manufacturer’s
instructions. FKBP5 protein levels were determined using Western
blot analysis.
Preparation and Transfection of FKBP5 and Mutant Plasmid
cDNA of FKBP5 was purchased from OriGene. FKBP5 was
cloned into the pEGFP plasmid and served as a template vector
for the site-directed mutagenesis. The FK1 domain of FKBP5
(FD67/68DV) was mutated using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) and the following primers:
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sense, (5′) CAAAGGAAAATTGTCAAATGGAAAGAAG-
GATGTTTCCAGTCATGATAGAAATGAACC (3′); antisense,
(5′) GGTTCATTTCTATCATGACTGGAAACATCCTTCTTTC-
CATTTGACAATTTTCCTTTG (3′). The mutation was confirmed
by DNA sequencing.
Cells were transfected either with the control vectors or with the
different FKBP5 expression vectors by electroporation using the
Nucleofector device (Amaxa Biosystems, Germany). Transfection effi-
ciency using nucleofection was about 80% to 90% as we reported
previously [18,19].
Electrophoretic Mobility Shift Assay
DNA:NF-κB binding was analyzed by using EMSA kit that was
purchased from Pierce. Nuclear fractions of FKBP5 overexpression
and control U87 or U251 cells were isolated using a Nuclear Extrac-
tion Kit purchased from Chemicon International. The isolation and
analysis procedures followed the protocols for the kits. The following
DNA fragments have been synthesized for EMSA analysis of DNA:
NF-κB protein binding.
Biotin-labeled: AGTTGAGGGGACTTTCCCAGGC;
Nonlabeled for competition: AGTTGAGGGGACTTTCC-
CAGGC;
Nonlabeled mutant for competition control: AGTTGAGGC-
GACTTTCCCAGGC.
Rapamycin Treatment
After FKBP5 and control siRNA–transfected A172 cells were
grown in DMEM with 10% FBS for 48 hours, rapamycin was added
to media to a final concentration of 100 ng/ml. Cells were grown in
DMEM with or without rapamycin for 24 hours and then were col-
lected for Western blot and apoptosis analysis.
Apoptosis Assay
Vybrant Apoptosis Assay Kit #9, purchased from Molecular Probes -
Invitrogen Detection Technologies (Eugene, OR), was used to conduct
an apoptosis assay. Briefly, FKBP5 and scrambled control siRNA–
transfected A172 cells were grown in DMEMwith 10% FBS. Cells were
harvested on day 3. Floating cells were collected by centrifugation at
4000 rpm for 5 minutes. Attached cells were trypsinized and inactivated
in DMEM with 10% FBS and centrifuged at 1200 rpm for 5 minutes.
Cells were washed with 1× annexin-binding buffer and resuspended at a
concentration of 1 × 106 cells/ml in 1× annexin-binding buffer. Cell sus-
pension (100 μl) was incubated with 5 μl of annexin-V–allophycocyanin
(APC) and 1 μl of 1 μM green staining working solution (SYTOX;
Molecular Probes - Invitrogen Detection Technologies) at 37°C in an
atmosphere of 5% CO2 for 15 minutes before flow cytometric analysis
(FACSCalibur; Becton-Dickinson, San Jose, CA).
Cell Growth Analysis
A day before transfection, A172 cells (1 × 105) in 500 μl were plated
onto 12-well plates. FKBP5 and control siRNA were transfected using
the silMPORTER kit from Upstate Inc. Cell number was counted
on days 3, 4, and 5 of transfection. On the day of the assay, 50 μl
of 10 mM EDTA was added to each well and incubated at 37°C for
2 minutes. We applied 450 μl of 1× PBS to suspend the cells and cell
suspension was collected in a 5-ml tube. Five hundred microliters of 1×
PBS was added to the cells remaining in the well and collected in the
same tube. The cell suspension was kept on ice and then counted for
20 seconds using a flow cytometer and microscope with Trypan Blue
staining. To analyze the effect of FKBP5 overexpression on the cell
growth, FKBP5-overexpressed or control U87 cells (5 × 104) were
plated in a 24-well plate. Cells grew in DMEM/10% FBS/500 μg/
ml G418 media for up to 4 days. Cell numbers were counted on days
1 and 4 using a microscope and Trypan Blue staining.
Western Blot Analysis
Cell lysates were collected in radioimmunoprecipitation buffer
(50 mM Tris-HCl, pH 8.0, 150 mMNaCl, 1% NP-40, 0.5% sodium
deoxycholate, and 0.1% SDS) with protease inhibitors (Roche,
Nonenwald, Germany). Electrophoresis was performed on 10%
SDS-PAGE gel (Bio-Rad, Hercules, CA) and transferred onto PVDF
Plus membrane using the Bio-Rad Mini-Protean II transfer system.
RNA Extraction
Total RNA was isolated from nontumor brain tissues (i.e., from epi-
lepsy surgeries and postmortem from patients with causes of death other
than brain disease) and brain tumor samples (i.e., glioblastomas, astro-
cytomas and oligodendrogliomas) using an RNeasy Lipid Tissue Mini
RNA Isolation Kit (Qiagen Science, MD) following the manufacturer’s
instructions. The quality of the RNA samples was determined by mea-
suring the absorbance of RNA samples at 260 nm as well as by electro-
phoresis through agarose gels and staining with ethidium bromide. The
18S and 28S RNA bands were visualized under ultraviolet lighting.
Reverse Transcriptional Reaction
Reverse transcription of RNA was done in a final volume of 20 μl
containing 13 RT-PCR buffer (500 mM each of deoxynucleotide tri-
phosphate, 3 mM MgCl2, 75 mM KCl, 50 mM Tris-HCl, pH 8.3),
10 U RNasin RNase inhibitor (Promega Corp., Madison, WI), 10 mM
DTT, 50 U Superscript II RNase H2 reverse transcriptase (Life Tech-
nologies, Inc., Gaithersburg, MD), 1.5 mM random hexamers (Phar-
macia, Uppsala, Sweden), and 1 μg of total RNA. The samples were
incubated at 20°C for 10 minutes and 42°C for 30 minutes, and reverse
transcriptase was inactivated by heating at 99°C for 5 minutes and cool-
ing at 5°C for 5 minutes.
Real-Time PCR Amplification
All PCR reactions were performed using a real-time RT-PCR system
(ABI Prism 7000 Sequence Detection System; Perkin-Elmer Applied
Biosystems). Primers for the FKBP5 gene were chosen with the assis-
tance of the computer program, Vector NTI (InforMax Corporation,
Invitrogen Life Science Software, Frederick, MD). We conducted
BLASTN searches against ref_Seq_rna to confirm the total gene spec-
ificity of the nucleotide sequences chosen for the primers and the
absence of DNA polymorphisms. To avoid amplification of contami-
nating genomic DNA, the two primers were placed in two different
exons. For each PCR run, 8 μl of 30-fold diluted cDNA was mixed
with 2 μl of primer mixture (10 μM/primer) and 10 μl of Platinum
SYBR Green qPCR SuperMix UDG with ROX (#11744; Invitrogen)
on ice. The thermal cycling conditions consisted of an initial denatura-
tion step at 95°C for 4 minutes, 45 cycles at 95°C for 30 seconds,
60°C for 30 minutes, and 70°C for 1 minute, and finished with incu-
bation at 72°C for 7 minutes.
Statistical Analysis
The results are presented as the mean ± SD. Data were analyzed
using analysis of variance and Student’s t test to determine the level of
significance between the different groups.
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Results
Expression of FKBP5 in Glioma
FKBP5 is distributed in many human tissues, including kidney, liver,
heart, ovary, etc., but not in brain, lung, and colon [6]. Employing
microarray analysis, we found that FKBP5 expression was highly up-
regulated in glioma specimens and its expression level correlated with
glioma grade (Figure 1A). For example, the median level of FKBP5 of
GBM (grade IV glioma tumor) was much higher than that found in
lower-grade tumors, such as astrocytoma (grade II or III) and oligo-
dendroglioma (grade II). To verify the microarray results, we randomly
picked samples from a tumor bank. Using real-time RT-PCR and
Western blot analysis, we further confirmed the overexpression of
FKBP5 at bothmRNA and protein levels in glioma specimens (Figure 1,
B and C ). Moreover, statistical analysis of patient survival showed that
the expression of FKBP5 correlated with overall GBM patient survival
rates (Figure 1D); that is, the GBM patients with high levels of FKBP5
had shorter survival than those with intermediate levels. Moreover, we
examined FKBP5 expression in glioma cell lines at both RNA and pro-
tein levels using real-time RT-PCR and Western blot analysis. Figure 1,
E and F, shows that FKBP5 is expressed in different glioma cell lines, and
the expression level of FKBP5 varies in the different cell lines.
Figure 1. FKBP5 expression is upregulated in glioma tumor and expression of FKBP5 in GBM patients correlates with overall survival. (A)
Microarray analysis was conducted with glioma tumor samples from 192 patients, including 87 GBMs, 49 oligodendrogliomas, 28 as-
trocytomas, 11 mixed gliomas, and 21 nontumor brain tissues obtained from epilepsy surgery. (B) Real-time PCR analysis validated the
microarray data. The P value of GBM versus nontumor samples is less than 0.01, and the P value of oligodendrogliomas versus non-
tumor samples is less than 0.05. (C) Protein expression of FKBP5 in GBM and oligodendroglioma specimens was analyzed by Western
blot analysis. The image analysis of FKBP5 protein bands versus β-actin shows that FKBP5 was highly expressed in GBM specimens
compared to oligodendroglioma specimens. (D) Probability of GBM patient survival and FKBP5 expression level. The yellow line indi-
cates the survival of GBM patients with intermediate levels of FKBP5 mRNA (i.e., FKBP5 expression in the tumors falls within the two-
fold change compared to the nontumor samples) in specimens; the red line indicates the survival of GBM patients with high levels of
FKBP5 mRNA (i.e., the threshold for FKBP5 upregulation was two-fold or more) in specimens; and the blue line indicates the overall
GBM patient survival rate. The number of patients with upregulated FKBP5 expression in the group is 74, whereas the number of pa-
tients with intermediate levels of FKBP5 is 13, and no tumor showed downregulation of FKBP5 expression (i.e., two-fold or less). The
t test analysis showed that the P value between the intermediate and upregulated levels is less than 0.01. (E) mRNA level of FKBP5 in
glioma tumor cell lines was analyzed by real-time PCR. (F) Protein expression of FKBP5 in glioma tumor cell lines was detected by
Western blot analysis using 10% SDS-PAGE.
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Influence of FKBP5 on Glioma Cell Growth
We chose A172 cells for our experiments because the Western blot
analysis and real-time RT-PCR data showed that this cell line expresses
relatively high levels of FKBP5 mRNA and protein. To examine the
function of FKBP5 in glioma cells, we used the RNA interference tech-
nique to knock down the expression of FKBP5 in A172 cells. The real-
time RT-PCR analysis showed that more than 80% of FKBP5 mRNA
was knocked down by siRNA transfection (Figure 2A). Western blot
assay confirmed the depletion of FKBP5 protein expression in these
cells (shown in Figure 2B). Cell growth analysis showed that cell growth
was significantly suppressed after FKBP5 siRNA had been transfected
for up to 5 days (Figure 2C ). In contrast, we overexpressed FKBP5
protein in U87 cells that have very low levels of endogenous FKBP5
(shown in Figure 1, E and F ). Figure 2D showed that overexpression of
FKBP5 enhanced glioma cell U87 growth dramatically. Therefore, we
conclude that FKBP5 expression helps regulate glioma cell growth.
Depletion of FKBP5 Induces Glioma Cell Apoptosis and
FKBP5 Regulates Signal Transduction of NF-κB Pathway
An apoptosis assay was conducted using annexin-V staining. Apop-
totic cells were stained by APC-conjugated annexin-V. Depletion of
FKBP5 induced apoptosis in A172 cells (Figure 3A).
FKBP5 was found to be essential for NF-κB pathway activation in
melanoma and leukemia [13,16]. NF-κB consists of heterodimers
from five different proteins, i.e., p50, p65, Rel-B, cRel, and p52.
These dimers are trapped in the cytoplasm through a noncovalent
interaction with one specific protein inhibitor (e.g., IκBα, IκBβ, or
IκBɛ). In response to a variety of specific signals, these inhibitors are
phosphorylated by the IKK kinase complex and are subsequently de-
graded by the proteasome. When IKK kinase activity is inhibited,
these inhibitors are not phosphorylated, and the expression of these
inhibitors will be accumulated. Tumor necrosis factor-alpha treatment
showed that IκBα became more stable when cells became apoptotic
[20]. To test whether FKBP5 expression mediates the signal transduc-
tion of NF-κB in glioma tumors, we examined the expression of IκBα
and phosphorylated-Rel A (p65) in both FKBP5-depleted and
FKBP5-overexpressed cells. Shown in Figure 3B, the IκBα expression
level was higher in FKBP5-depleted A172 cells than control cells,
whereas lower in FKBP5-overexpressed U87 cells than control cells,
suggesting that expression of FKBP5 mediates the stability of IκBα.
Meanwhile, real-time RT-PCR data showed that the mRNA level of
IκBα was not regulated by FKBP5 expression (data not shown), sug-
gesting that FKBP5 does not regulate transcription of IκBα. The ex-
pression level of phosphorylated NF-κB (Ser536) was also regulated by
the expression of FKBP5; that is, phosphorylation of NF-κB was en-
hanced by FKBP5 depletion but inhibited by FKBP5 overexpression
(Figure 3B). In addition, EMSA results (Figure 3C ) showed that DNA:
NF-κB proteins interaction in glioma cells was enhanced by the over-
expression of FKBP5. These results together indicate that NF-κB acti-
vation in the glioma cells is mediated by the expression of FKBP5.
FKBP5 Modulates Glioma Cell Response to Rapamycin
Treatment through Regulating Signaling Transduction of
NF-κB Pathway
Rapamycin is an inhibitor of FKBPs, including FKBP5 and
FKBP12, the latter forming a complex with rapamycin and mTOR
Figure 2. FKBP5 expression mediates glioma tumor cell growth. (A) mRNA expression of FKBP5 was analyzed with real-time PCR after
siRNA was transfected into A172 cells for 3, 4, and 5 days. (B) Protein expression, after siRNA vectors were transfected in A172 cells for
3 and 5 days, or FKBP5 was overexpressed in U87 cells for 4 days, was analyzed by Western blot using 10% SDS-PAGE. (C) A172 cell
growth was analyzed at 3 and 5 days after siRNA transfection. The statistical analysis showed that the P value between the FKBP5-
depleted and control cells is less than 0.01. (D) U87 cell growth was analyzed after GFP vector or GFP-FKBP5 vector was transfected into
U87 cells for 4 days. The P value for the cell numbers at day 4 of GFP-FKBP5–overexpressed cells versus GFP cells is less than 0.01.
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to inhibit mTOR downstream signals. To understand the conse-
quences of rapamycin’s inhibiting properties on FKBP5, we hypoth-
esized that depletion of FKBP5 would block the effect of rapamycin
on glioma cell proliferation. To test this hypothesis, we treated glioma
cells depleted of FKBP-5 using siRNA with 100 ng/ml rapamycin. We
observed that FKBP5 depletion actually sensitized the cells to rapamy-
cin (Figure 4A).
The percentage of apoptotic cells in control siRNA–transfected
A172 cells (i.e., which were reported to be rapamycin-resistant cells)
was not significantly regulated by rapamycin treatment. When treat-
ing FKBP5-depleted A172 cells with 100 ng/ml rapamycin, however,
we found that cell death was augmented by 15%.
Cell sensitivity to rapamycin treatment was found to relate to
phosphatase and tensin homolog on chromosome ten (PTEN) status.
It has been reported that cancer cells with aberrant PTEN alleles are
more sensitive to rapamycin treatment than those with wild-type
PTEN [21]. To further test whether the effect of FKBP5 on modu-
lating rapamycin resistance is dependent on PTEN status, we treated
LN18 and LN229 glioma cells that expressed wild-type PTEN
(shown in Figure 4B) with rapamycin after cells were transfected
with scrambled control siRNA or FKBP5 siRNA for 48 hours.
FKBP5 depletion induced cell apoptosis in the LN18 and LN229
cells by 29% and 13%, respectively, and the apoptosis of FKBP5-
depleted cells was further enhanced by rapamycin treatment by
about 19.3% and 27.1%, respectively (Figure 4A). However, rapa-
mycin treatment did not significantly induce apoptosis in the control-
transfected cells. Taken together, these data suggest that the effect of
FKBP5 on cell sensitivity to rapamycin treatment was independent of
PTEN status.
To further validate that expression of FKBP5 mediates cell re-
sponse to rapamycin treatment, we overexpressed FKBP5 in U87,
the most sensitive glioma cell line that responds to rapamycin treatment
(IC50 ≈ 1000 nM), to examine the response of FKBP5-overexpressed
U87 to rapamycin treatment. Cell growth analysis (Figure 4C ) showed
that about 50% of cell growth of control vector–transfected U87 cells
was suppressed by rapamycin treatment, whereas no cell growth was
Figure 3. Depletion of FKBP5 expression induces glioma cell apoptosis, and expression of FKBP5 mediates IKBα expression and DNA
binding ability of NF-κB proteins. (A) Cell apoptosis was analyzed using Vybrant Apoptosis Assay Kit #9 (Molecular Probes) after FKBP5
protein was knocked down for 3 days. The kit contains recombinant annexin-V conjugated to APC, and SYTOX Green nucleic acid stain.
The SYTOX Green dye is impermeable to live cells and apoptotic cells, but stains dead cells with an intense green fluorescence by binding
to cellular nucleic acids. After staining, apoptotic cells show red fluorescence and very little green fluorescence, dead cells show a higher
level of green and red fluorescence, and live cells show little or no fluorescence. (B) Western blot anti-IκBα was used to examine the effect
of FKBP5 expression on IκBα expression in glioma cells. FKBP5 was depleted in A172 cells by RNAi, but overexpressed in U87 cells by
transfection of FKBP5 plasmid. Total cell lysate of A172 was collected after FKBP5 or control siRNA were transfected for 3 days, whereas
the total cell lysate of U87 was collected after transfection for 48 hours. Proteins were separated on 10% SDS-PAGE and transferred to the
PVDF membrane. The blots were stained with anti–IκBα antibody and anti–β-actin antibody. (C) EMSA assay was used to examine the
effect of FKBP5 expression on the DNA binding ability of NF-κB proteins in glioma cells. U87 or U251 cells were transfected with control
plasmid or FKBP5 plasmid for 48 hours. Nuclei fractions of transfected U87 or U251 cells were isolated using Nuclear Extraction Kit (Cat
# 2900; Chemicon). EMSA assay was conducted with LightShift Chemiluminescent EMSA Kit (Cat #20148; Pierce). Two controls were
included in the assay. Lane 5 shows a positive DNA and protein binding and shift of the biotin-EBNA DNA. Lane 6 demonstrates that the
signal shift observed in Lane 5 can be prevented by competition from excess nonlabeled DNA.
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suppressed by rapamycin treatment when wt-FKBP5 was overexpressed
in U87 cells. These data further support the findings that FKBP5 me-
diates glioma cell sensitivity to rapamycin treatment.
The peptidyl-prolyl isomerase activity in FKBP5 protein was
found to catalyze the isomerization of peptidyl-prolyl imide bonds
in the α subunit of the IKK kinase complex and is required for IKK
function [12]. Barent et al. [22] have shown that the double-point mu-
tant FD67DV in the PPIase domain of FKBP5 was able to disrupt
FKBP5 PPIase activity by 90% and to avoid potential artifacts associ-
ated with FK506.
Residues Phe and Asp in the FKBP (PPIase) domain are highly
conserved residues throughout the FKBP family, and the corre-
sponding positions in FKBP12 are required for PPIase activity [23,24].
Importantly, this double mutation does not alter the FKBP5 interac-
tion with progesterone receptor or HSP90 [22]. Therefore, we
adopted this mutation in our experiment to test the effect of FKBP5
on NF-κB signal transduction. Coimmunoprecipitation data (shown
in Figure 4D) suggested that mutating the FK1 domain of FKBP5
did not interrupt the interaction of HSP90 and FKBP5 but dramati-
cally regulated the interaction of IKKα and FKBP5. Cell response to
rapamycin treatment (Figure 4C ) showed that overexpression of
FKBP5 mutant 67 did not alter U87 cell response to rapamycin treat-
ment, although overexpression of wt-FKBP5 significantly inhibited
U87 cell response to rapamycin treatment, suggesting that interaction
of FKBP5 and IKK plays an important role in glioma cell sensitivity to
rapamycin treatment.
Using NF-κB inhibitor SN50 to block NF-κB pathway, we further
verified the effect of FKBP5 and the signal transduction of NF-κB
pathway on glioma cell sensitivity to rapamycin treatment. In this
experiment, U87 GFP or U87 GFP-FKBP5 cells were pretreated
with NF-κB inhibitor SN50 for 30 minutes and then treated with
rapamycin. Cell growth analysis (Figure 4C ) showed that cell growth
of U87 GFP or U87 GFP-FKBP5 that was treated with SN50 and
rapamycin was not significantly modulated by FKBP5 expression, in-
dicating that blocking the NF-κB signal abolished the effect of
FKBP5 on the cell response to rapamycin. Taken together, these re-
sults suggest that FKBP5 is upstream protein of NF-κB pathway and
can regulate signal transduction of the NF-κB pathway, and that glioma
cell response to rapamycin treatment can be regulated by FKBP5 ex-
pression through signal transduction of the NF-κB pathway.
Figure 4. FKBP5 expression regulates cell sensitivity to rapamycin treatment through the signal transduction of NF-κB pathway. (A) The
percentage of apoptotic cells was analyzed using Vybrant Apoptosis Assay Kit #9 (Molecular Probes). Glioma cells A172, LN18, and
LN229 were transfected with FKBP5 or control siRNA for 3 days before 100 nM rapamycin was added into the medium for 48 hours of
incubation. Cells (both floating and attached cells) were collected in annexin-V staining buffer. Then the cells were stained with recom-
binant annexin-V conjugated to APC, and SYTOX Green nucleic acid stain. After staining, apoptotic cells were analyzed by flow cytom-
eter. (B) Expression of PTEN was analyzed by Western blot analysis using 10% SDS-PAGE. (C) 1000 nM of rapamycin was applied
to treat U87 GFP, U87 GFP-FKBP5, U87 GFP-FKBP5 mut67 cells as well as U87 GFP and U87 GFP-FKBP5 cells that were pretreated
with 100 μg/ml SN50, for 2 days. Cell growth both with and without rapamycin treatment was analyzed by counting cells using a he-
macytometer. The percentage of cell growth was calculated by dividing the cell number with the cell number of nontreated U87-GFP
cells. The P value for the cell numbers of nontreated cells versus treated cells is less than 0.05, with the exception of U87 GFP-FKBP5–
overexpressed cells. (D) Total cell lysates of U87 GFP-FKBP5 or U87 GFP-FKBP5 mutant67 were coimmunoprecipitated against anti-GFP
antibody at 4°C overnight. Western blot analysis was performed with anti-IKKα, anti-HSP90, and anti-FKBP5 antibody after proteins were
separated on 10% SDS-PAGE.
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Discussion
FKBP5 was initially identified by studying the FK506 complex
and its binding proteins [25]. Subsequent studies revealed that
FKBP5 bound to HSP90 and associated with steroid receptors to
form nuclear receptors [3]. Studies also demonstrated that FKBP5
transcript levels in lymphocytes were glucocorticoid-inducible
[26,27], but the function and expression of FKBP5 in cancer cells
was little known. Expression of FKBP5 was only identified in pros-
tate specimens [28] and melanoma cell lines [16]. To the best of the
authors’ knowledge, there are no published studies about the expres-
sion of FKBP5 in glioma tumors. An examination of the tissue dis-
tribution of FKBP5 found that expression of FKBP5 in brain tissue
was not detectable by Western blot analysis [6]. Employing mi-
croarray assay, we showed that FKBP5 was highly expressed in glioma
specimens compared to nontumor specimens. Our RT-PCR and
Western blot assay data validated the microarray findings. Owing to
the lack of a robust antibody for FKBP5 immunohistochemistry, we
analyzed FKBP5 expression in primary tumor culture using western
blot analysis as well as RT-PCR of FKBP5 mRNA in GBM xenografts
in nude rats using human-specific primers. Both analyses have previ-
ously shown FKBP5 expression in glioma cells (data not shown).
These results together suggest that FKBP5 is expressed in glioma cells
both in vitro and in vivo.
When immunophilin FKBP5 combines with FK506, it can inhibit
calcineurin [29]. FKBP5 was also found to be associated with heat
shock proteins HSP70/HSP90, MAP3K1, MAP3K7, IKKα/CHUK
(conserved helix-loop-helix ubiquitous kinase), IKKɛ, and cRel [12,
30]. As a consequence of these interactions, FKBP5 may play a novel
role in cell survival, proliferation and differentiation. Overexpressing
FKBP5 in UT7/Mpl cells showed that FKBP5 enhanced antiapoptotic
property. Using the siRNA approach to knock down the expression of
FKBP5 in glioma cells, we found that glioma cells became apoptotic and
cell growth was suppressed, whereas cell growth was enhanced by
FKBP5 overexpression. Studying the phosphorylation of NF-κB p65
and DNA–NF-κB binding, we found that FKBP5 regulated the signal-
ing transduction of NF-κB pathway.
Rapamycin (sirolimus) is a macrolide antibiotic produced by Strep-
tomyces hygroscopicus, which is currently used as an immunosup-
pressive drug to prevent renal graft rejection [31]. In addition to
inhibiting the isomerase activity of FKBPs [3], rapamycin can bind
to FKBP12, form a complex with mTOR, and inhibit mTOR, thereby
preventing further phosphorylation of p70S6K, 4E-BP1 and, indirectly,
other proteins involved in transcription, translation, and cell cycle con-
trol [31,32]. For its properties of inhibiting mTOR signal transduction,
rapamycin becomes a promising anticancer therapeutic agent. Preclin-
ical studies [21,33,34] showed that the loss of PTEN function con-
ferred an increased sensitivity to mTOR inhibitors. Herein, we
demonstrated that depletion of FKBP5 augmented glioma cell sensitiv-
ity to rapamycin treatment, and the synergy was independent of PTEN
status. A recent study on the signal transduction of mTOR and NF-κB
demonstrated that overexpressing mTOR in endothelial cells inhibited
NF-κB activity [35]. This study further showed that rapamycin treat-
ment blocked mTOR downstream signals in phosphatidylinositol 3-
kinase/Akt/mTOR pathway by inhibiting the phosphorylation of
p70S6K protein, but enhanced NF-κB activity and its nuclear trans-
location [35]. These findings indicated that rapamycin resistance
might be attributed, at least partly, to the survival signals induced
by NF-κB activation in rapamycin treatment. FKBP5 has been shown
to exert peptidyl-prolyl isomerase activity that catalyzed the isomeri-
zation of peptidyl-prolyl imide bonds in the α subunit of the IKK
kinase complex and to be required for IKK function as well as NF-κB
activation and translocation [12,13]. Several studies [13,14,16], includ-
ing our own, have demonstrated that depletion of FKBP5 expression in
tumor cells can enhance the expression of IκBα. It is reasonable to as-
sume that the depletion of FKBP5 can consequently abrogate the sur-
vival signal of rapamycin-induced NF-κB activation. This notion was
confirmed by interrupting FKBP5-IKK interaction using the FKBP5
mutant, in which we found that overexpression of FKBP5 mutant re-
stored U87 sensitivity to rapamycin treatment. Because we have demon-
strated that the effect of FKBP5 on rapamycin treatment is PTEN-
status–independent, our results offer a promising strategy to improve
the treatment of rapamycin-resistant glioma tumors in the clinic.
Our combined studies on the expression and function of FKBP5
in glioma cells demonstrate that FKBP5 plays a crucial role in glioma
cell survival, growth and proliferation. Apoptotic synergy induced by
the depletion of FKBP5 in rapamycin treatment suggests that FKBP5
may play a significant role in modulating rapamycin resistance, and
this implies that modulating FKBP5 activity may improve the sensi-
tivity of rapamycin-resistant cells to rapamycin treatment. Studying
the FKBP5-mediated signal transductions will reveal ways to develop
new drugs specifically targeting the immunophilin and consequently
targeting rapamycin resistance in glioma cells.
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